Photosensitivity Reactions to Vandetanib: Redevelopment after Sequential Treatment with Docetaxel.
10.5021/ad.2011.23.S3.S314
- Author:
Young Min SON
1
;
Joo Young ROH
;
Eun Kyung CHO
;
Jong Rok LEE
Author Information
1. Department of Dermatology, Gachon University of Medicine and Science, Gil Hospital, Incheon, Korea. dmjj1@gilhospital.com
- Publication Type:Case Report
- Keywords:
Docetaxel;
Photosensitivity;
Vandetanib
- MeSH:
Diarrhea;
Hypertension;
Piperidines;
Protein-Tyrosine Kinases;
Quinazolines;
Receptor, Epidermal Growth Factor;
Taxoids;
Transfection;
Vascular Endothelial Growth Factor Receptor-2
- From:Annals of Dermatology
2011;23(Suppl 3):S314-S318
- CountryRepublic of Korea
- Language:English
-
Abstract:
Vandetanib (ZD6474, Zactima(TM)) is a novel, orally available inhibitor of different intracellular signaling pathways involved in tumor growth, progression, and angiogenesis, including vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and rearranged during transfection tyrosine kinase activity. The most frequently reported adverse events attributed to vandetanib include diarrhea, elevated aminotransferase, asymptomatic corrected QC interval prolongation, and hypertension. In a few randomized, double-blinded studies, cutaneous adverse events including these general symptoms have been reported, but there are only a few reports on the photosensitivity reaction to vandetanib domestically as conducted by dermatologists. In this report, we describe two cases of photosensitivity reactions induced by vandetanib. After improvement with steroid and antihistamine, the photosensitivity reaction was redeveloped by sequential treatment with docetaxel.
